Confluence Wealth Services Inc. Sells 123 Shares of Becton, Dickinson and Company (NYSE:BDX)

Confluence Wealth Services Inc. lessened its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,330 shares of the medical instruments supplier’s stock after selling 123 shares during the quarter. Confluence Wealth Services Inc.’s holdings in Becton, Dickinson and Company were worth $803,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. WR Wealth Planners LLC boosted its position in Becton, Dickinson and Company by 1.4% during the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after buying an additional 42 shares during the period. Clear Creek Financial Management LLC grew its stake in shares of Becton, Dickinson and Company by 5.1% in the second quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock worth $210,000 after purchasing an additional 44 shares during the last quarter. Sound Income Strategies LLC increased its holdings in Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the period. Central Pacific Bank Trust Division raised its position in Becton, Dickinson and Company by 22.5% during the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 45 shares during the last quarter. Finally, Capital Advisors Ltd. LLC lifted its holdings in Becton, Dickinson and Company by 3.6% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 1,394 shares of the medical instruments supplier’s stock worth $326,000 after buying an additional 48 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $235.24 on Monday. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $259.92. The company has a market cap of $67.99 billion, a PE ratio of 48.40, a P/E/G ratio of 1.75 and a beta of 0.43. The stock has a 50-day moving average of $237.56 and a 200-day moving average of $235.09. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. The company had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. Becton, Dickinson and Company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.96 earnings per share. On average, equities research analysts predict that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Evercore ISI raised their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Raymond James dropped their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Stifel Nicolaus increased their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.